Impact of delayed prescription fill on readmission rates for chronic obstructive pulmonary disease and heart failure

Kovacik, Aaron; Bell, Paula C.; King, Sean R.; Mallon, Amy; Renfroe, James; Dyer, Charles R.

doi:10.1016/j.japh.2018.04.017

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is particularly important because delayed prescription filling of HF medications has been associated with an increase in hospital admissions, and multiple studies have identified cost as a reason for sacubitril/valsartan discontinuation. 13,15,54…”

Section: Cost/accessmentioning

confidence: 99%

Inpatient Initiation of Sacubitril/Valsartan

et al. 2020

View full text Add to dashboard Cite

Objective: Discuss the literature and describe strategies to overcome barriers of inpatient initiation of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF). Data Sources: A PubMed, EMBASE, and Google Scholar literature search (January 2014 to June 2020) limited to English language articles was conducted with the following terms: sacubitril/valsartan, initiation, inpatient, hospitalized, B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), diuretic, cost, and cost-effectiveness. Study Selection and Data Extraction: Included articles described inpatient initiation of sacubitril/valsartan or described its impact on BNP, NT-proBNP, diuretic dosing, or cost of care. Data Synthesis: A total of 20 studies were identified based on included search terms. Conclusions: Sacubitril/valsartan should be considered for hemodynamically stable patients with HFrEF (New York Heart Association class II or III), potassium <5.2 mmol/L, without a history of angioedema, and after a 36-hour washout from angiotensin-converting enzyme (ACE) inhibitor or aliskiren, if applicable. An appropriate dose can be determined based on the patient’s previous ACE inhibitor or angiotensin receptor blocker dose and/or blood pressure along with patient-specific factors. To overcome barriers of use, the following are recommended: NT-proBNP or BNP with establishment of a new baseline 1 month after initiation may be used for prognosis or diagnosis; careful monitoring of diuretic requirements; utilization of multiple strategies to overcome cost barriers; and use of interdisciplinary care.

show abstract

Section: Cost/accessmentioning

confidence: 99%

Inpatient Initiation of Sacubitril/Valsartan

et al. 2020

View full text Add to dashboard Cite

show abstract

Systematic Review and Meta-analysis of Pharmacist-Led Transitions of Care Services on the 30-Day All-Cause Readmission Rate of Patients with Congestive Heart Failure

et al. 2019

View full text Add to dashboard Cite

Medication reconciliation in in-patients with chronic pathologies: a narrative review

María Vega,

Mora-Villaseñor,

Córdova-Mariángel

et al. 2024

PPIJ

View full text Add to dashboard Cite

Objective: To analyze the effectiveness of the medication reconciliation process by pharmacists at the hospital level in patients with chronic non-communicable diseases, evidenced through the analysis of readmissions and the acceptance of pharmaceutical interventions. Method: A narrative bibliographic review was conducted in databases of the University of Concepción between 2011 and 2021. Keywords used in the search included medication reconciliation, hospital readmission, clinical pharmacy, discrepancy, among others. The search was conducted in both English and Spanish. Clinical studies, trials, descriptive observational studies, and analytical observational studies (case and control reports) were included, involving a population over 18 years old with chronic or non-communicable diseases and reconciliation at admission, during the stay, and at hospital discharge. Results: A total of 36 articles were reviewed, of which only 23 compared the impact on unplanned readmissions within 30 days of hospital discharge, and 4 mentioned visits to the emergency department during the same period. Only 15 articles presented physician acceptance of interventions carried out by pharmacists during the medication reconciliation process, with an acceptance rate of at least 60%. Conclusions: Based on this bibliographic review, it can be concluded that medication reconciliation has an impact on the quality of care. This is reflected in a reduction in both the number of visits to the emergency department and hospital readmissions during the 30 days following discharge.

show abstract

Impact of delayed prescription fill on readmission rates for chronic obstructive pulmonary disease and heart failure

Abstract: Delaying discharge prescription fills resulted in a nonsignificant increase in the rate of HF readmission but did not increase the rate of readmission for COPD. Rate of delaying prescription fill was not statistically greater for any of the baseline characteristics.

Cited by 3 publications

References 12 publications

Inpatient Initiation of Sacubitril/Valsartan

Inpatient Initiation of Sacubitril/Valsartan

Systematic Review and Meta-analysis of Pharmacist-Led Transitions of Care Services on the 30-Day All-Cause Readmission Rate of Patients with Congestive Heart Failure

Medication reconciliation in in-patients with chronic pathologies: a narrative review

Contact Info

Product

Resources

About